Literature DB >> 2835690

Different roles for type A and type B monoamine oxidase in regulating synaptic dopamine at D-1 and D-2 receptors associated with adenosine-3',5'-cyclic monophosphate (cyclic AMP) formation.

J Liccione1, A J Azzaro.   

Abstract

The roles of multiple forms of monoamine oxidase (MAO) in regulating the synaptic concentration of dopamine, in the vicinity of dopamine receptors associated with cyclic AMP formation, was examined in striatal slices of the rat. d-Amphetamine (0.1 mumol/l to 20 mumol/l) caused a concentration-related increase in cyclic AMP formation, which correlated (in superfusion experiments) with the release of endogenously-formed dopamine. In the presence of (-)sulpiride (50 mumol/l), cyclic AMP formation was significantly increased at every concentration of d-amphetamine tested. At the same time, this concentration of (-)sulpiride had no effect on DA release. Inhibition of type A MAO with clorgyline (0.1 mumol/l) significantly enhanced the increase in cyclic AMP formation seen after d-amphetamine. By contrast, inhibition of type B MAO with deprenyl (0.1 mumol/l) was without effect on this action of d-amphetamine. At high concentrations of d-amphetamine (20 mumol/l), however, deprenyl + clorgyline treatment enhanced cyclic AMP formation to a greater extent than with clorgyline alone. Similar results could be obtained at lower concentrations of d-amphetamine (5 mumol/l), but only after inhibition of the dopamine neuronal reuptake system with nomifensine (30 mumol/l). Furthermore, in the presence of nomifensine, deprenyl alone was also able to significantly increase the cyclic AMP formation seen after d-amphetamine (5 mumol/l). In the presence of (-)sulpiride, relatively similar results were obtained following all MAO inhibitor treatments. These findings support the notion that type A MAO plays the primary role in regulating dopamine concentrations at D-1 and D-2 receptors within synapses of rat striatal tissue.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2835690     DOI: 10.1007/BF00169242

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  44 in total

1.  Opposing actions of D-1 and D-2 dopamine receptor-mediated alterations of adenosine-3',5'-cyclic monophosphate (cyclic AMP) formation during the amphetamine-induced release of endogenous dopamine in vitro.

Authors:  A J Azzaro; J Liccione; J Lucci
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1987-08       Impact factor: 3.000

Review 2.  Substrate-selective monoamine oxidases--inhibitor, tissue, species and functional differences.

Authors:  D L Murphy
Journal:  Biochem Pharmacol       Date:  1978       Impact factor: 5.858

3.  Effects of amphetamines on regional tryptophan hydroxylase activity and synaptosomal conversion of tryptophan to 5-hydroxytryptamine in rat brain.

Authors:  S Knapp; A J Mandell; M A Geyer
Journal:  J Pharmacol Exp Ther       Date:  1974-06       Impact factor: 4.030

4.  (-)Deprenyl in the treatment of Parkinson's disease.

Authors:  W Birkmayer; P Riederer; M B Youdim
Journal:  Clin Neuropharmacol       Date:  1982       Impact factor: 1.592

Review 5.  Two dopamine receptors: biochemistry, physiology and pharmacology.

Authors:  J C Stoof; J W Kebabian
Journal:  Life Sci       Date:  1984-12-03       Impact factor: 5.037

6.  Nomifensine: a new potent inhibitor of dopamine uptake into synaptosomes from rat brain corpus striatum.

Authors:  P Hunt; M Kannengiesser; J Raynaud
Journal:  J Pharm Pharmacol       Date:  1974-05       Impact factor: 3.765

Review 7.  Possible role for cyclic nucleotides and phosphorylated membrane proteins in postsynaptic actions of neurotransmitters.

Authors:  P Greengard
Journal:  Nature       Date:  1976-03-11       Impact factor: 49.962

8.  Time course of nigrostriatal degeneration in parkinson's disease. A detailed study of influential factors in human brain amine analysis.

Authors:  P Riederer; S Wuketich
Journal:  J Neural Transm       Date:  1976       Impact factor: 3.575

9.  Dynamics of endogenous catecholamine release from brain fragments of male and female rats.

Authors:  J Becker; V D Ramirez
Journal:  Neuroendocrinology       Date:  1980-07       Impact factor: 4.914

10.  The metabolism of dopamine by both forms of monoamine oxidase in the rat brain and its inhibition by cimoxatone.

Authors:  C J Fowler; M S Benedetti
Journal:  J Neurochem       Date:  1983-06       Impact factor: 5.372

View more
  1 in total

Review 1.  Dopamine metabolism and neurotransmission in primate brain in relationship to monoamine oxidase A and B inhibition.

Authors:  M B Youdim; P Riederer
Journal:  J Neural Transm Gen Sect       Date:  1993
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.